Chemours (NYSE: CC) reported Q4 EPS of $0.05, $0.02 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.33 billion.

Key Full Year 2026 Outlook5

Consolidated Net Sales growth in the range of 3 to 5%
Adjusted EBITDA between $800 million and $900 million
Free Cash Flow Conversion above 25%

For earnings history and earnings-related data on Chemours (CC) click here.